Press Releases
- Rezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021
- Rezolute Strengthens Board of Directors with Key Appointments of Leading Rare Disease Experts
- Rezolute to Participate in Upcoming Investor Conferences in March
- Rezolute Reports Second Quarter Fiscal 2021 Financial Results
- Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
